Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06182072 · ClinicalTrials.gov registry record · Phase 1
ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)
A Phase 1 study of Pancreatic Ductal Adenocarcinoma (PDAC), sponsored by ProDa BioTech.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT06182072 is a Phase 1 study of Pancreatic Ductal Adenocarcinoma (PDAC) that is actively recruiting participants, run by ProDa BioTech. The registered enrollment target is 46 participants, below the 294-participant average among 16 other Pancreatic Ductal Adenocarcinoma (PDAC) trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06182072, a Phase 1 study of Pancreatic Ductal Adenocarcinoma (PDAC), is actively recruiting participants, sponsored by ProDa BioTech.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label Phase I/Ib dose-escalation, dose-expansion clinical trial of the safety, pharmacokinetics and clinical activity of ProAgio combined with gemcitabine, nab-paclitaxel (G-nP) or gemcitabine, nab-paclitaxel (G-nP) and atezolizumab in previously untreated subjects with metastatic pancreatic ductal adenocarcinoma (PDAC)
Conditions Studied
Interventions
- DRUG ProAgio Dose Levels (DL) 1,2,3,4
- DRUG Gemcitabine, nab paclitaxel
Study Locations (1)
Alabama
- O'Neal Comprehensive Cancer Center, University of Alabama - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2023-09-14 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06182072
The ClinicalTrials.gov registry entry for NCT06182072 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 294-participant average among 16 other Pancreatic Ductal Adenocarcinoma (PDAC) trials with a reported enrollment target (84% lower). The listed sponsor is ProDa BioTech, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Ductal Adenocarcinoma (PDAC) appearing as the primary indexed condition, and to 2 interventions - of which ProAgio Dose Levels (DL) 1,2,3,4 is the first listed.
NCT06182072 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT06182072 about?
NCT06182072 is a clinical study titled "ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)". This is an open-label Phase I/Ib dose-escalation, dose-expansion clinical trial of the safety, pharmacokinetics and clinical activity of ProAgio combined with gemcitabine, nab-paclitaxel (G-nP) or gemcitabine, nab-paclitaxel (G-nP) and atezolizumab in previously untreated subjects with metastatic pa...
What is the current status of trial NCT06182072?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2023-09-14. Estimated completion is 2028-06-30.
What conditions does trial NCT06182072 study?
This clinical trial studies the following conditions: Pancreatic Ductal Adenocarcinoma (PDAC).
What interventions are being tested in trial NCT06182072?
The interventions under investigation include: ProAgio Dose Levels (DL) 1,2,3,4 (DRUG), Gemcitabine, nab paclitaxel (DRUG).
Who is sponsoring clinical trial NCT06182072?
This trial is sponsored by ProDa BioTech, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06182072 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Ductal Adenocarcinoma (PDAC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
RECRUITING · Phase 1
-
Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.